BioCentury
ARTICLE | Top Story

Aptalis files for $500 million IPO

December 27, 2013 1:06 AM UTC

Gastrointestinal company Aptalis Holdings Inc. (Mont-Saint-Hilaire, Quebec) filed to raise up to $500 million in an IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate suspension to treat active duodenal ulcers and Zenpep pancrelipase to treat exocrine pancreatic insufficiency. For the fiscal year ended Sept. 30, Aptalis reported revenues of $687.9 million. ...